The benefits of trastuzumab in the treatment of human epidermal receptor  2-positive breast cancer as a function of exposure time

Name: The benefits of trastuzumab in the treatment of human epidermal receptor 2-positive breast cancer as a function of exposure time
Creator: Felipe Andrés Cordero da Luz
Published: 2022-01-17T13:47:11.893Z
Keywords: Breast Cancer

Luz, Felipe Andrés Cordero da; Marinho, Eduarda; Nascimento, Camila; Marques, Lara; Delfino, Patrícia; Antonioli, Rafael; Silva, Marcelo; Araújo, Rogério

doi:10.17632/t3yb6fy69b.3

The benefits of trastuzumab in the treatment of human epidermal receptor 2-positive breast cancer as a function of exposure time

Published: 17 January 2022| Version 3 | DOI: 10.17632/t3yb6fy69b.3

Contributors:

Felipe Andrés Cordero da Luz, Eduarda Marinho, Camila Nascimento, Lara Marques, Patrícia Delfino, Rafael Antonioli, Marcelo Silva, Rogério Araújo

Description

Shorter times of trastuzumab exposition (<1 year) could protect from disease progression in breast cancer patients. Survival analysis of continuous predictor was used to obtain optimal cut-offs regarding DMFS, DFS, and OS.

The benefits of trastuzumab in the treatment of human epidermal receptor 2-positive breast cancer as a function of exposure time

Description

Files

Categories

Licence